SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa
24. Januar 2024 07:00 ET
|
SparingVision
SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa Positive recommendation received from the Data Safety Monitoring Board (DSMB) enabling...
SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial
30. August 2023 07:00 ET
|
SparingVision
SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial Lead gene therapy asset, SPVN06, reported to be well-tolerated in first...
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics
12. Juli 2023 07:00 ET
|
SparingVision
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics SparingVision remains focused on in vivo genomic medicines, with SPVN20, a GIRK-based gene therapy candidate, expected to reach...
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer
09. Dezember 2021 07:00 ET
|
SparingVision
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer Raffaella Toso, PhD, joins as VP Corporate Development & Alliance Management and...
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
19. März 2021 08:00 ET
|
SparingVision
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting Paris, March 19, 2021 – SparingVision (“the Company”), a genomic...
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
19. März 2021 02:00 ET
|
SparingVision
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting Paris, March 19, 2021 – SparingVision (“the Company”), a genomic...
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
29. Januar 2021 07:00 ET
|
SparingVision
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board ...
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
29. Januar 2021 01:00 ET
|
SparingVision
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board ...